ArticleGland surgery2025
Patterns and costs of breast reconstruction in Chinese plastic surgery department: a study from national quality control databases (2022-2023).
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Factors Associated with Standardized Diagnosis and Treatment of Breast Cancer: A Real-World Multicenter Study.Cancer management and research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast reconstruction after mastectomy is crucial for physical and psychological recovery. While reconstruction rates have risen globally under supportive policies, utilization in China remains low, and nationwide data on patterns, costs, and access are scarce. This study aims to provide the first comprehensive analysis of the current status, costs, and regional disparities of breast reconstruction in Chinese plastic surgery department based on national quality control databases. Methods: We analyzed three national databases [the National Clinical Improvement System (NCIS), the National Medical Quality Control Platform of Plastic and Aesthetic Medicine (QCP-PAM), and the Hospital Quality Monitoring System (HQMS)]. Variables included surgical volume, reconstruction type, perioperative antibiotic usage, surgical site infection rate, hospitalization cost, and self-pay ratio. Descriptive statistics, cross-database comparisons, and Pearson's correlations with socioeconomic indicators [per capita gross domestic product (GDP), urbanization rate] were performed. Results: In 2022, NCIS recorded 30,530 breast cancer surgeries, with a phase I reconstruction rate of 6.4%. HQMS identified 490 reconstructions across 15 China's provincial-level administrative divisions (PLADs) in 2023, with mean hospitalization cost of CNY 53,695 and self-pay of 61.7%. Regional disparities were striking, with self-pay ranging from <10% to 100%. GDP correlated positively with cost (r=0.45) and negatively with self-pay (r=-0.60); urbanization was also negatively correlated with self-pay (r=-0.50). Conclusions: This first nationwide analysis highlights low reconstruction rates, heavy financial burden, and marked geographic inequities. Expanded insurance, stronger infrastructure, and quality monitoring are needed to improve access. Limitations include incomplete provincial coverage, lack of detailed outcomes, and potential underreporting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.